Ketorolac Trometamol Rompharm

Ketorolac Trometamol, the active ingredient in Ketorolac Trometamol Rompharm, is a nonsteroidal anti‑inflammatory drug (NSAID) formulated as an injectable solution for intramuscular or intravenous administration. It provides potent analgesia for the short‑term management of moderate to severe acute pain, such as post‑operative pain, in adult patients.

GNH USA supplies Ketorolac Trometamol Rompharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory conformity across global markets and meeting the specific needs of healthcare providers.

Ketorolac Trometamol is an NSAID that provides analgesia by inhibiting prostaglandin synthesis in acute pain conditions.

- Post‑operative pain: rapid relief of moderate to severe pain following surgical procedures. - Acute musculoskeletal pain: reduction of pain intensity after injuries or trauma. - Short‑term severe pain: effective non‑opioid option for managing acute pain when opioid therapy is not indicated.

Ketorolac Trometamol may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: transient feeling of sickness. - Headache: mild to moderate intensity. - Injection site pain: local discomfort at the administration site. - Dizziness: occasional light‑headedness. - Gastrointestinal upset: includes dyspepsia or mild abdominal discomfort.

Serious or Rare Side Effects: - Gastrointestinal bleeding or ulceration: potentially life‑threatening. - Renal impairment: reduced kidney function, especially in at‑risk patients. - Severe hypersensitivity reactions: including anaphylaxis or skin rash. - Cardiovascular events: such as myocardial infarction or stroke. - Hematologic abnormalities: thrombocytopenia or bleeding disorders. - Stevens‑Johnson syndrome: rare but serious skin reaction.

Ketorolac Trometamol requires careful assessment before use to minimise risk.

- Renal function: evaluate kidney status and avoid in severe renal impairment. - Bleeding risk: contraindicated in active peptic ulcer disease or coagulopathy. - Cardiovascular disease: use cautiously in patients with coronary artery disease. - Pregnancy and lactation: safety not established; generally avoided. - Concomitant NSAIDs or anticoagulants: increased risk of gastrointestinal bleeding. - Store at ambient temperature: keep in original container, protect from light and moisture.

Ketorolac Trometamol can interact with several drug classes, requiring vigilance.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin, heparin): heightened bleeding risk. - Other NSAIDs or COX‑2 inhibitors: additive gastrointestinal toxicity. - Selective serotonin reuptake inhibitors (SSRIs): increased potential for bleeding.

Moderate Interactions (Monitor Closely): - ACE inhibitors: may reduce renal perfusion when combined. - Diuretics: risk of renal impairment, especially in dehydrated patients. - Lithium: possible increase in serum lithium concentrations.